The cancer testis antigen 1 A (CTAG1A, also known as CTAG1B/NY-ESO-1) peptide SLLMWITQC in complex with HLA-A*02:01 is an active target for engineered T-cell based therapy in multiple myeloma, synovial sarcoma, and advanced melanoma [51]. This evidence concerns the gene HLA-A and plasma cell myeloma.